Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Agios Pharmaceuticals

Evaluate

Thumbnail
June 08, 2023

Asco 2023 movers – maintaining the momentum

Several biotech stocks maintained throughout Asco the momentum they had going into the meeting, and intrigue over Tigit continued.

Thumbnail
June 04, 2023

Asco 2023 – liver tox casts a pall over Servier’s Indigo readout

Vorasidenib, potentially the first targeted therapy for low-grade glioma, comes at a toxicity price.

Article image
Vantage logo
May 12, 2023

EHA 2023 – earlier leak limits the surprise factor

Article image
Vantage logo
September 01, 2022

Novo’s $1.1bn pro Forma deal

Article image
Vantage logo
August 08, 2022

Pfizer bets $5.4bn against gene therapies in sickle cell

Hopefully the acquisition of Global Blood Therapeutics will go better than Pfizer’s last foray into sickle cell deal-making.

Article image
Vantage logo
August 03, 2022

Rigel makes Forma wait for olutasidenib payday

Article image
Vantage logo
March 02, 2022

US FDA approval tracker: February 2022

Article image
Vantage logo
February 28, 2022

A big year for sickle cell

Novel approaches including gene editing are creeping towards approval.

Article image
Vantage logo
February 18, 2022

Agios’s pricing dilemma

How can the company wring the most value from Pyrukynd?

Article image
Vantage logo
February 01, 2022

Imara gets a second shot in sickle cell

Will upping the dose and changing the primary endpoint pay off?

Article image
Vantage logo
January 26, 2022

Go or no go? Pdufa resolutions eyed for J&J and Amryt

February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up